ERBB2 and breast cancer: Despite the significant clinical benefits of TZMB, its biggest limitation is primary and acquired resistance; only one third of HER2+ BC patients initially obtain therapeutic benefits, and many primary responders develop resistance within one year of treatment initiation [12,13,14,15,16,17].